Sol-gel Technologies Ltd. · NASDAQ:SLGL
Sol-gel Technologies — Investor Presentation (November 2021)
19 slides from Sol-gel Technologies's investor presentation, Nov 16, 2021
Slide 1: Sol-Gel Technologies
$ Sol- Gel ey nced Topical Therapy
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,
Slide 3: Pursuing Leadership in Dermatology: Innovative Pipeline of Topical Skin Medications
pre-clinical phase II phase III filed research phase I pre-clinical phase II phase III filed research phase I FDA approval07/26/21 EPSOLAY®Benzoyl Peroxide Cream, 5%Inflammatory Lesions of Rosacea TWYNEO® Tretinoin and Benzoyl Peroxide Cream, 0.1%/3%Acne Vulgaris SGT-510Topical RoflumilastPsoriasis
Slide 4: Achieving FDA Approval and Building Our Future: Investor Highlights
ACHIEVING FDA APPROVAL and BUILDING our FUTURE Investor Highlights Completed development of EPSOLAY and TWYNEO on time Gained FDA approval for TWYNEOEPSOLAY pre-approval inspection is pending Built a strong balance sheet that currently allows us to finance our activities until the end of 2023 Secure
Slide 5: Strategic Partnership with Market Leader Galderma
TWYNEO® EPSOLAY® MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO Strategic Partnership with Market Leader Galderma
Slide 6: Galderma Leads the US Acne and Rosacea Markets
MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO Galderma Leads the US Acne and Rosacea Markets
Slide 7: Galderma is Committed to Innovation
MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO Galderma is Committed to Innovation
Slide 8: Strategic Partnership with Market Leader Galderma: Deal Terms
TWYNEO® EPSOLAY® MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO Strategic Partnership with Market Leader Galderma Up to $15 million in upfront and product approval payments Mid- to high-teen percentage of net sales royaltiesUp to an additional $9 million in sales milestone paymentsOption
Slide 9: Sale of Generic Assets to Padagis
2 generic drugs: acyclovir cream and ivermectin cream8 unapproved generic programs FOCUSING on INNOVATIVE PIPELINE while SECURING NON-DILUTIVE FUNDING Sale of Generic Assets to Padagis
Slide 10: Focusing on Innovative Pipeline while Securing Non-Dilutive Funding
FOCUSING on INNOVATIVE PIPELINE while SECURING NON-DILUTIVE FUNDING Sale of Generic Assets to Padagis Focusing on innovative pipeline Reducing the need to raise dilutive capital $21 million in quarterly installments over 24 monthsProceed with 50/50 gross profit-sharing collaboration on 2 programs en
Slide 11: TWYNEO: Offering Comprehensive Treatment for Acne Patients
Acne vulgaris is a multifactorial disease. Even though benzoyl peroxide and tretinoin are widely prescribed separately and have a complimentary mechanism of action, so far, they could not be applied concomitantly because benzoyl peroxide decomposes tretinoinTWYNEO contains a fixed‑dose combination o
Slide 12: Treating Severe Acne Patient
BASELINE “Severe”; 29 inflamed lesions31 non-inflamed lesions; 1 nodule WEEK 12 “Moderate”; 9 inflamed lesions5 non-inflamed lesions; No nodules TREATING SEVERE ACNE PATIENT Subject 507-003 || 18 Years Old | Female | White | Not Hispanic or Latino* * Individual results vary
Slide 13: EPSOLAY: Offering a New Effective Topical Treatment
Inflammatory lesions of rosacea resemble acne vulgaris, except that comedones (whiteheads and blackheads) are absent and only inflammatory lesions existEPSOLAY contains encapsulated benzoyl peroxide, using Sol‑Gel’s patented technology. Benzoyl peroxide is an effective antibacterial drug that is not
Slide 14: Treating Severe Rosacea Patient
BASELINE “Severe”; 31 inflamed lesions WEEK 2 “Clear”; No inflamed lesions “Clear”; No inflamed lesions WEEK 12 “Almost Clear”; 1 inflamed lesion WEEK 8 “Clear”; No inflamed lesions TREATING SEVERE ROSACEA PATIENT Subject 116-009 || 41 Years Old | Female | White | Not Hispanic or Latino* WEEK 4 * In
Slide 15: Developing First Erlotinib Topical Drug: SGT-210
Initiate clinical development with a higher concentration of erlotinib in H2 22 DEVELOPING FIRST ERLOTINIB TOPICAL DRUG SGT-210 for Palmoplantar Keratoderma and other Skin Conditions NEXTSTEPSSGT-210 12 patent applications for erlotinib in various skin conditions (as of August 16, 2021) Potential IP
Slide 16: Developing Novel Tapinarof Cream: SGT-310
Initiate clinical development in H2 22 DEVELOPING NOVEL TAPINAROF CREAM SGT-310 for Psoriasis and other Skin Conditions NEXTSTEPSSGT-310 31 patent applications for tapinarof in various skin conditions (as of August 16, 2021) Potential IP protection until 2042 SGT-310 is intended to be an alternative
Slide 17: Developing Novel Roflumilast Topical Drug: SGT-510
SGT-510 is designed to be potentially more effective than roflumilast cream, 0.3%, for which an NDA was already submitted to the FDA DEVELOPING NOVEL ROFLUMILAST TOPICAL DRUG SGT-510 for Psoriasis and other Skin Conditions NEXTSTEPSSGT-510 A patent application was filedPotential IP protection until
Slide 18: Building a Strong Balance Sheet: Financial Profile
Financials September 30, 2021 Cash and Investments $45.6 million Shares Outstanding 23,119,068 ordinary shares Expected Partnership Payments EPSOLAY approval milestone payment (if approved this year); Quarterly payments by Padagis; Royalties from Galderma Cash Runway Based on expected payments from
Slide 19: Sol-Gel Technologies
$ Sol- Gel ey nced Topical Therapy
Sol-Gel Technologies — Investor Presentation (November 2021) on 6ix